The IDIAP Jordi Gol
Who we are
Organization
Quality Certification
Strategic plan
Annual reports
HRS4R
Transparency
Research
Territorial Support Units (USR)
Research Areas
Publications
Projects
CEIm
CEIM presentation
How to Submit the Documentation to the CEIM
Rates of The CEI
CEI meeting calendar
Regulations and links of interest CEI
Services and Platforms
AGICAP
Grants to Finance Research
Clinical Trial Monitoring
Platforms Questionnaires
Sidiap Database
Real World Lab
Tools-Help
Scientific Tools
Management Tools
IDIAP Management Tools
Innovation
News
Link GIR
Acces GIR
Login
Català
Castellano
English
The IDIAP Jordi Gol
Who we are
Organization
Quality Certification
Strategic plan
Annual reports
HRS4R
Transparency
Research
Territorial Support Units (USR)
Research Areas
Publications
Projects
CEIm
CEIM presentation
How to Submit the Documentation to the CEIM
Rates of The CEI
CEI meeting calendar
Regulations and links of interest CEI
Services and Platforms
AGICAP
Grants to Finance Research
Clinical Trial Monitoring
Platforms Questionnaires
Sidiap Database
Real World Lab
Tools-Help
Scientific Tools
Management Tools
IDIAP Management Tools
Innovation
News
Link GIR
Search
Most popular
COL·LABORA
Menu
English
Català
Español
Home
Àrees Recerca
DIABETES
DAP_CAT
DAP_CAT
Grup de Recerca Epidemiològica en Diabetis des de l´Atenció Primària (DAP_CAT)
Group leader
Josep Franch Nadal
josep.franch@gmail.com
Presentation
Team
Publications
Projects
News
Presentation
Team
Publications
Projects
News
Projects
Group projects
Caracterización del riesgo cardiovascular antes del primer evento cardiovascular prematuro en Catalunya
Principal investigators:
José Manuel Mata Cases
Code:
4R17/041
Start year:
2017
Funders:
Generalitat Catalunya
Incidència de la diabetis tipus 2 a Catalunya (estudi di@bet.es II .cat)
Principal investigators:
Josep Franch Nadal
Code:
4R17/043
Start year:
2017
Funders:
Generalitat Catalunya
Patient characteristics and cardiovascular and mortality outcomes in patients with high cardiovascular risk and type 2 diabetes mellitus initiating treatment with sodium-glucose co-transporter-2 inhibitors and other antidiabetic medications
Principal investigators:
Josep Franch Nadal
Code:
4R17/071
Start year:
2017
Funders:
AstraZeneca Farmacéutica Spain, S.A.
Global and country-specific rates and trends in the incidence of diagnosed type 2 diabetes (GLOBALDIAB)
Principal investigators:
José Manuel Mata Cases
Code:
4R17/084
Start year:
2017
Funders:
ICS - Institut Català de la Salut
Estudio sobre los resultados de la adición de una sulfonilurea, un iDPP4 o un iSGLT2 como segundo antidiabético en pacientes con DM2 en tratamiento con metformina e insuficiente control glucémico. Estudio eControl Metf+
Principal investigators:
Josep Franch Nadal
Code:
4R17/101
Start year:
2017
Funders:
AstraZeneca Farmacéutica Spain, S.A.
Anterior
1
2
3
4
5
…
12
Següent
Board of Trustees
Collaborators
Accreditations